<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01178528</url>
  </required_header>
  <id_info>
    <org_study_id>CTG001-07</org_study_id>
    <nct_id>NCT01178528</nct_id>
  </id_info>
  <brief_title>Heart Rate Reduction in Heart Failure</brief_title>
  <acronym>CARVIVA-HF</acronym>
  <official_title>Effect of Ivabradine, Carvedilol or Their Combination in Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with heart failure (HF) have a limited exercise tolerance,few pharmacological
      interventions have been proven effective in improving exercise capacity. At the presence
      there i conflicting evidence on the effectiveness of beta-blockers on exercise capacity.
      Ivabradine has been shown to improve prognosis in patients with ischemic heart disease, left
      ventricular dysfunction and heart rate &gt; 70 bpm. The association of ivabradine and atenolol
      has been proven effective in increasing exercise tolerance in patients with ischemic heart
      disease. Aim of the present study is to evaluate the effect of heart rate reduction with
      ivabradine, carvedilol or their combination in patients with heart failure of ischemic
      origin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with chronic heart failure of ischemic origin (120) Stable coronary artery disease
      Acute coronary syndromes &gt; 3 months Revascularization procedures &gt; 3 months Naive on heart
      rate reducing agents New York Heart Association (NYHA) Class II III 6 minute walking test
      (6MW) tolerance between 200 and 400 m Stable medications for the past 3 months

      Treatment Ivabradine up to 7.5 mg b.i.d. Carvedilol up to 25 mg b.i.d. Carvedilol and
      Ivabradine up to 12.5/5 mg b.i.d.

      Efficacy measure Intention to treat Exercise tolerance Quality of life
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exercise Tolerance Assessed by 6 Minute Walking Test</measure>
    <time_frame>3 months</time_frame>
    <description>Distance measured at 6 minute walking test. The 6 minute walking test was performed according to standardised procedure at baseline, before inclusion (at least 1 week after baseline evaluation), and at the end of the study. Patients who had not done at least two tests in the past underwent two practice 6 minute walking tests at least 3 days apart. Results are expressed in terms of distance walked (metres). The test was supervised by a physical therapist.
Patients were asked to walk at their own maximal pace a 100 m long hospital corridor. At the beginning of the last (6th) minute of the test a standard phrase of encouragement was told. Patients were allowed to stop if signs or symptoms of significant distress occurred (dyspnea, angina), through they were instructed to resume walking as soon as possible.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal Oxygen Consumption</measure>
    <time_frame>3 months</time_frame>
    <description>Functional capacity was assessed by means of a cardiopulmonary exercise test with a bicycle ergometer with gas exchange monitoring (Vmax 29 C, SensorMedics). Peak oxygen consumption was defined as the maximal oxygen consumption (MVO2) observed during exercise.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>3 months</time_frame>
    <description>Quality of life (QoL) was evaluated using the Visual Analogue Scale (VAS) which is a global measurement of QoL, allowing a subjective assessment of the impact of the disease and treatment. Patients are asked to indicate their current state in a line from 0 (worst state) to 10 (best state), with higher values therefore representing a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) Class</measure>
    <time_frame>3 months</time_frame>
    <description>The 1994 NYHA Classification system is a measure of functional status. It was designed for clinical assessment of patients by physicians as NYHA class I, II, III, or IV, on the basis of patient's limitations in physical activities caused by cardiac symptoms.
Class I describes patients with cardiovascular disease (CVD) but without resulting limitation of physical activity. There is no objective evidence of CVD.
Class II describes patients with CVD resulting in slight limitation of physical activity. There is objective evidence of minimal CVD.
Class III describes patients with CVD resulting in marked limitation of physical activity. There is objective evidence of moderately severe CVD.
Class IV describes patients with CVD resulting in inability to carry on any physical activity without discomfort. There is objective evidence of severe CVD.
Here we report data on number of patients showing an improvement by at least one NYHA class according to treatment allocation.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Ivabradine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7.5 mg bd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carvedilol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>up to 25 mg bd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&quot;Drug:Carvedilol&quot; and &quot;Drug:Ivabradine&quot;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>up to 12.5/5 mg bd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ivabradine</intervention_name>
    <description>7.5 mg bd</description>
    <arm_group_label>Ivabradine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>&quot;Drug:Carvedilol&quot; and &quot;Drug:Ivabradine&quot;</intervention_name>
    <description>up to 12.5/5 mg bd</description>
    <arm_group_label>&quot;Drug:Carvedilol&quot; and &quot;Drug:Ivabradine&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol</intervention_name>
    <description>25 mg bd</description>
    <arm_group_label>Carvedilol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  heart failure II-III

          -  ischemic origin

          -  stable medications from at least 3 months

          -  &gt; 3 months from an acute ischemic syndrome or revascularization procedure

          -  naive on heart rate reducing agents

        Exclusion Criteria:

          -  bradycardia

          -  hypersensitivity or contraindications to study drugs

          -  exercise tolerance at 6 minute walking test &lt;100 m or &gt;400 m
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurizio Volterrani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS San Raffaele</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giuseppe MC Rosano, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>IRCCS San Raffaele</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cristiana Vitale, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>IRCCS San Raffaele</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Clinical and Basic Research - IRCCS San Raffaele</name>
      <address>
        <city>Roma</city>
        <zip>00100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS San Raffaele</name>
      <address>
        <city>Roma</city>
        <zip>00100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.escardio.org</url>
    <description>European Society Cardiology guidelines</description>
  </link>
  <reference>
    <citation>Fasullo S, Cannizzaro S, Maringhini G, Ganci F, Giambanco F, Vitale G, Pinto V, Migliore G, Torres D, Sarullo FM, Paterna S, Di Pasquale P. Comparison of ivabradine versus metoprolol in early phases of reperfused anterior myocardial infarction with impaired left ventricular function: preliminary findings. J Card Fail. 2009 Dec;15(10):856-63. doi: 10.1016/j.cardfail.2009.05.013. Epub 2009 Jul 3.</citation>
    <PMID>19944362</PMID>
  </reference>
  <reference>
    <citation>Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). Eur J Heart Fail. 2010 Jan;12(1):75-81. doi: 10.1093/eurjhf/hfp154. Epub 2009 Nov 5.</citation>
    <PMID>19892778</PMID>
  </reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2010</study_first_submitted>
  <study_first_submitted_qc>August 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2010</study_first_posted>
  <results_first_submitted>September 19, 2013</results_first_submitted>
  <results_first_submitted_qc>September 29, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 30, 2014</results_first_posted>
  <last_update_submitted>September 29, 2014</last_update_submitted>
  <last_update_submitted_qc>September 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Raffaele</investigator_affiliation>
    <investigator_full_name>Giuseppe M.C. Rosano</investigator_full_name>
    <investigator_title>Principal investigato</investigator_title>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>heart rate</keyword>
  <keyword>ivabradine</keyword>
  <keyword>carvedilol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ivabradine</title>
          <description>up to 7.5 mg b.i.d.</description>
        </group>
        <group group_id="P2">
          <title>Carvedilol</title>
          <description>up to 25 mg b.i.d.</description>
        </group>
        <group group_id="P3">
          <title>Carvedilol and Ivabradine</title>
          <description>up to 12.5 / 5 mg b.i.d.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ivabradine</title>
          <description>up to 7.5 mg b.i.d.</description>
        </group>
        <group group_id="B2">
          <title>Carvedilol</title>
          <description>up to 25 mg b.i.d.</description>
        </group>
        <group group_id="B3">
          <title>Carvedilol and Ivabradine</title>
          <description>up to 12.5 / 5 mg b.i.d.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="42"/>
            <count group_id="B4" value="121"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>MALE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEMALE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Exercise Tolerance Assessed by 6 Minute Walking Test</title>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="346.7" spread="112.0"/>
                    <measurement group_id="B2" value="379.0" spread="96.3"/>
                    <measurement group_id="B3" value="358.2" spread="107.6"/>
                    <measurement group_id="B4" value="361.3" spread="105.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Maximal Oxygen Consumption</title>
          <units>mL/Kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.05" spread="2.1"/>
                    <measurement group_id="B2" value="12.3" spread="2.6"/>
                    <measurement group_id="B3" value="12.4" spread="2.5"/>
                    <measurement group_id="B4" value="12.25" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Quality of Life</title>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.3" spread="0.5"/>
                    <measurement group_id="B2" value="4.6" spread="0.8"/>
                    <measurement group_id="B3" value="4.7" spread="0.8"/>
                    <measurement group_id="B4" value="4.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>New York Heart Association (NYHA) class</title>
          <description>The NYHA Classification system is a measure of functional status. Class II describes patients with cardiovascular disease (CVD) resulting in slight limitation of physical activity and comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain. There is objective evidence of minimal CVD. Class III describes patients with CVD resulting in marked limitation of physical activity and comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation, dyspnea, or anginal pain. There is objective evidence of moderately severe CVD.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>class II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>class III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Exercise Tolerance Assessed by 6 Minute Walking Test</title>
        <description>Distance measured at 6 minute walking test. The 6 minute walking test was performed according to standardised procedure at baseline, before inclusion (at least 1 week after baseline evaluation), and at the end of the study. Patients who had not done at least two tests in the past underwent two practice 6 minute walking tests at least 3 days apart. Results are expressed in terms of distance walked (metres). The test was supervised by a physical therapist.
Patients were asked to walk at their own maximal pace a 100 m long hospital corridor. At the beginning of the last (6th) minute of the test a standard phrase of encouragement was told. Patients were allowed to stop if signs or symptoms of significant distress occurred (dyspnea, angina), through they were instructed to resume walking as soon as possible.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ivabradine</title>
            <description>up to 7.5 mg b.i.d.</description>
          </group>
          <group group_id="O2">
            <title>Carvedilol</title>
            <description>up to 25 mg b.i.d.</description>
          </group>
          <group group_id="O3">
            <title>Carvedilol and Ivabradine</title>
            <description>up to 12.5 / 5 mg b.i.d.</description>
          </group>
        </group_list>
        <measure>
          <title>Exercise Tolerance Assessed by 6 Minute Walking Test</title>
          <description>Distance measured at 6 minute walking test. The 6 minute walking test was performed according to standardised procedure at baseline, before inclusion (at least 1 week after baseline evaluation), and at the end of the study. Patients who had not done at least two tests in the past underwent two practice 6 minute walking tests at least 3 days apart. Results are expressed in terms of distance walked (metres). The test was supervised by a physical therapist.
Patients were asked to walk at their own maximal pace a 100 m long hospital corridor. At the beginning of the last (6th) minute of the test a standard phrase of encouragement was told. Patients were allowed to stop if signs or symptoms of significant distress occurred (dyspnea, angina), through they were instructed to resume walking as soon as possible.</description>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="474.8" spread="127.3"/>
                    <measurement group_id="O2" value="435.7" spread="121.3"/>
                    <measurement group_id="O3" value="453.1" spread="87.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life</title>
        <description>Quality of life (QoL) was evaluated using the Visual Analogue Scale (VAS) which is a global measurement of QoL, allowing a subjective assessment of the impact of the disease and treatment. Patients are asked to indicate their current state in a line from 0 (worst state) to 10 (best state), with higher values therefore representing a better outcome.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ivabradine</title>
            <description>up to 7.5 mg b.i.d.</description>
          </group>
          <group group_id="O2">
            <title>Carvedilol</title>
            <description>up to 25 mg b.i.d.</description>
          </group>
          <group group_id="O3">
            <title>Carvedilol and Ivabradine</title>
            <description>up to 12.5 / 5 mg b.i.d.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life</title>
          <description>Quality of life (QoL) was evaluated using the Visual Analogue Scale (VAS) which is a global measurement of QoL, allowing a subjective assessment of the impact of the disease and treatment. Patients are asked to indicate their current state in a line from 0 (worst state) to 10 (best state), with higher values therefore representing a better outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="0.9"/>
                    <measurement group_id="O2" value="4.1" spread="0.6"/>
                    <measurement group_id="O3" value="6.1" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximal Oxygen Consumption</title>
        <description>Functional capacity was assessed by means of a cardiopulmonary exercise test with a bicycle ergometer with gas exchange monitoring (Vmax 29 C, SensorMedics). Peak oxygen consumption was defined as the maximal oxygen consumption (MVO2) observed during exercise.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ivabradine</title>
            <description>7.5 mg b.i.d.</description>
          </group>
          <group group_id="O2">
            <title>Carvedilol</title>
            <description>up to 25 mg b.i.d.</description>
          </group>
          <group group_id="O3">
            <title>Carvedilol and Ivabradine</title>
            <description>up to 12.5 / 5 mg b.i.d.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximal Oxygen Consumption</title>
          <description>Functional capacity was assessed by means of a cardiopulmonary exercise test with a bicycle ergometer with gas exchange monitoring (Vmax 29 C, SensorMedics). Peak oxygen consumption was defined as the maximal oxygen consumption (MVO2) observed during exercise.</description>
          <units>mL/Kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" spread="1.9"/>
                    <measurement group_id="O2" value="12.9" spread="2.4"/>
                    <measurement group_id="O3" value="14.7" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New York Heart Association (NYHA) Class</title>
        <description>The 1994 NYHA Classification system is a measure of functional status. It was designed for clinical assessment of patients by physicians as NYHA class I, II, III, or IV, on the basis of patient’s limitations in physical activities caused by cardiac symptoms.
Class I describes patients with cardiovascular disease (CVD) but without resulting limitation of physical activity. There is no objective evidence of CVD.
Class II describes patients with CVD resulting in slight limitation of physical activity. There is objective evidence of minimal CVD.
Class III describes patients with CVD resulting in marked limitation of physical activity. There is objective evidence of moderately severe CVD.
Class IV describes patients with CVD resulting in inability to carry on any physical activity without discomfort. There is objective evidence of severe CVD.
Here we report data on number of patients showing an improvement by at least one NYHA class according to treatment allocation.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ivabradine</title>
            <description>up to 7.5 mg b.i.d.</description>
          </group>
          <group group_id="O2">
            <title>Carvedilol</title>
            <description>up to 25 mg b.i.d.</description>
          </group>
          <group group_id="O3">
            <title>Carvedilol and Ivabradine</title>
            <description>up to 12.5 / 5 mg b.i.d.</description>
          </group>
        </group_list>
        <measure>
          <title>New York Heart Association (NYHA) Class</title>
          <description>The 1994 NYHA Classification system is a measure of functional status. It was designed for clinical assessment of patients by physicians as NYHA class I, II, III, or IV, on the basis of patient’s limitations in physical activities caused by cardiac symptoms.
Class I describes patients with cardiovascular disease (CVD) but without resulting limitation of physical activity. There is no objective evidence of CVD.
Class II describes patients with CVD resulting in slight limitation of physical activity. There is objective evidence of minimal CVD.
Class III describes patients with CVD resulting in marked limitation of physical activity. There is objective evidence of moderately severe CVD.
Class IV describes patients with CVD resulting in inability to carry on any physical activity without discomfort. There is objective evidence of severe CVD.
Here we report data on number of patients showing an improvement by at least one NYHA class according to treatment allocation.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ivabradine</title>
          <description>up to 7.5 mg b.i.d.</description>
        </group>
        <group group_id="E2">
          <title>Carvedilol</title>
          <description>up to 25 mg b.i.d.</description>
        </group>
        <group group_id="E3">
          <title>Carvedilol and Ivabradine</title>
          <description>up to 12.5 / 5 mg b.i.d.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>G Rosano</name_or_title>
      <organization>IRCCS San Raffaele</organization>
      <phone>0652252309</phone>
      <email>giuseppe.rosano@sanraffaele.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

